| 2027-05-01in 249 d | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 4568.TDaiichi Sankyo | Phase 1/2 | Acute Myeloid Leukemia | Active, not recruiting |
| 2027-05-01in 249 d | VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study | ADGMAdagio Medical | Not applicable | Ventricular Tachycardia | Not yet recruiting |
| 2027-05-01in 249 d | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants | PFEPfizer | Phase 2 | Pneumococcal Disease | Active, not recruiting |
| 2027-05-02in 250 d | A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | PFEPfizer | Phase 3 | Eczema | Recruiting |
| 2027-05-04in 252 d | Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta | AMGNAmgen | Phase 3 | Osteogenesis Imperfecta | Active, not recruiting |
| 2027-05-05in 253 d | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | AZNAstraZeneca | Phase 1 | Systemic Lupus Erythematosus | Recruiting |
| 2027-05-05in 253 d | A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. | PFEPfizer | Phase 1 | Severe Hemophilia A | Recruiting |
| 2027-05-06in 254 d | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | SLDBSolid Biosciences Inc. | Phase 1/2 | Duchenne Muscular Dystrophy | Recruiting |
| 2027-05-06in 254 d | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | SNYSanofi | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| 2027-05-10in 258 d | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | REGNRegeneron Pharmaceuticals | Phase 1/2 | Ovarian Cancer | Recruiting |
| 2027-05-11in 259 d | Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | NVONovo Nordisk A/S | Phase 3 | Obesity | Active, not recruiting |
| 2027-05-12in 260 d | Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | NVONovo Nordisk A/S | Phase 3 | Overweight | Active, not recruiting |
| 2027-05-13in 261 d | A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis | PFEPfizer | — | Ulcerative Colitis | Active, not recruiting |
| 2027-05-13in 261 d | French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | SNYSanofi | — | Atopic Dermatitis | Recruiting |
| 2027-05-14in 262 d | A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | AZNAstraZeneca | Phase 3 | Polymyositis, Dermatomyositis | Recruiting |
| 2027-05-14in 262 d | A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat | NVONovo Nordisk A/S | Phase 1 | Fatty Liver Disease | Recruiting |
| 2027-05-14in 262 d | A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | PFEPfizer | Phase 1 | Pneumococcal Disease | Active, not recruiting |
| 2027-05-15in 263 d | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | MRNAModernaTX, Inc. | Phase 1 | Epstein-Barr Virus | Recruiting |
| 2027-05-15in 263 d | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | REGNRegeneron Pharmaceuticals | Phase 1/2 | MASH / Nonalcoholic Steatohepatitis | Recruiting |
| 2027-05-15in 263 d | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | RVMDRevolution Medicines, Inc. | Phase 1/2 | Colorectal Cancer | Recruiting |
| 2027-05-16in 264 d | A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy | NVONovo Nordisk A/S | Phase 2 | Heart Failure | Recruiting |
| 2027-05-17in 265 d | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | REGNRegeneron Pharmaceuticals | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | Recruiting |
| 2027-05-17in 265 d | Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP) | SNYSanofi | — | Polyneuropathy, Inflammatory Demyelinating, Chronic | Recruiting |
| 2027-05-18in 266 d | A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | NVONovo Nordisk A/S | Phase 3 | Overweight | Not yet recruiting |
| 2027-05-18in 266 d | A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration | SNYSanofi | Phase 1/2 | Age-Related Macular Degeneration | Active, not recruiting |
| 2027-05-20in 268 d | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | BIIBBiogen | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| 2027-05-20in 268 d | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | REGNRegeneron Pharmaceuticals | Phase 2 | Lung Cancer | Active, not recruiting |
| 2027-05-22in 270 d | Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease | AZNAstraZeneca | Phase 1 | Autosomal Dominant Polycystic Kidney Disease | Recruiting |
| 2027-05-24in 272 d | A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | AZNAstraZeneca | Phase 2 | Chronic Kidney Disease | Recruiting |
| 2027-05-24in 272 d | The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis | SNYSanofi | — | Atopic Dermatitis | Recruiting |
| 2027-05-25in 273 d | A Study of LAD191 in Adults With Hidradenitis Suppurativa | ALM.MCAlmirall, S.A. | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| 2027-05-25in 273 d | Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | IBRXImmunityBio, Inc. | Phase 2 | Relapsed B-Cell Non Hodgkin Lymphoma | Recruiting |
| 2027-05-26in 274 d | Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants | 4507.TShionogi | Phase 1 | Healthy Participants | Recruiting |
| 2027-05-26in 274 d | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | BIIBBiogen | Phase 4 | Amyotrophic Lateral Sclerosis | Active, not recruiting |
| 2027-05-26in 274 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | BMYBristol-Myers Squibb | Phase 1 | Lung Cancer | Active, not recruiting |
| 2027-05-26in 274 d | Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia | FDMT4D Molecular Therapeutics | Phase 1 | Choroideremia | Active, not recruiting |
| 2027-05-27in 275 d | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism | MBXMBX Biosciences | Phase 2 | Hypoparathyroidism | Active, not recruiting |
| 2027-05-27in 275 d | A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults | REGNRegeneron Pharmaceuticals | Phase 1 | Healthy Volunteer | Not yet recruiting |
| 2027-05-28in 276 d | A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus | ALNYAlnylam Pharmaceuticals | Phase 2 | Type 2 Diabetes | Recruiting |
| 2027-05-28in 276 d | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | AZNAstraZeneca | Phase 1/2 | Ovarian Cancer | Active, not recruiting |
| 2027-05-28in 276 d | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia | AZNAstraZeneca | Phase 3 | Hypercholesterolaemia | Not yet recruiting |
| 2027-05-28in 276 d | A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144 | AZNAstraZeneca | Phase 1 | Hepatic Impairment | Not yet recruiting |
| 2027-05-28in 276 d | A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2027-05-29in 277 d | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | AMGNAmgen | Phase 4 | Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization | Active, not recruiting |
| 2027-05-30in 278 d | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | ACRVAcrivon Therapeutics | Phase 2 | Endometrial Adenocarcinoma | Recruiting |
| 2027-05-30in 278 d | Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs | AZNAstraZeneca | — | Neurofibroma, Plexiform | Active, not recruiting |
| 2027-05-30in 278 d | Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy | AZNAstraZeneca | — | Asthma | Active, not recruiting |
| 2027-05-30in 278 d | A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis. | NVONovo Nordisk A/S | Phase 1 | ATTR Amyloidosis | Recruiting |
| 2027-05-30in 278 d | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | OLMAOlema Pharmaceuticals, Inc. | Phase 1 | Breast Cancer | Recruiting |
| May 2027≤ 279 d | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | AAPGAscentage Pharma Group Inc. | Phase 1 | Solid Tumors | Recruiting |
| May 2027≤ 279 d | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | ABBVAbbVie | Phase 3 | Migraine | Recruiting |
| May 2027≤ 279 d | A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | ABBVAbbVie | Phase 1 | Castration-Resistant Prostate Cancer | Active, not recruiting |
| May 2027≤ 279 d | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis | ABBVAbbVie | Phase 2 | Atopic Dermatitis | Active, not recruiting |
| May 2027≤ 279 d | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults. | ABBVAbbVie | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-05-31in 279 d | Effect of a Probiotic or Postbiotic on Gut Microbiome During Antibiotic Treatment | ADMThe Archer-Daniels-Midland Company | Not applicable | Microbiome | Not yet recruiting |
| 2027-05-31in 279 d | Pyruvate Kinase Deficiency Global Longitudinal Registry | AGIOAgios Pharmaceuticals, Inc. | — | Pyruvate Kinase Deficiency | Active, not recruiting |
| May 2027≤ 279 d | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | ALKSAlkermes, Inc. | Phase 3 | Narcolepsy | Recruiting |
| May 2027≤ 279 d | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | ALKSAlkermes, Inc. | Phase 3 | Narcolepsy | Recruiting |
| 2027-05-31in 279 d | A Study of LAD106 in Healthy Adult Participants | ALM.MCAlmirall, S.A. | Phase 1 | Healthy Volunteers | Recruiting |
| 2027-05-31in 279 d | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | AZNAstraZeneca | Phase 4 | Chronic Kidney Disease | Active, not recruiting |
| 2027-05-31in 279 d | Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer | AZNAstraZeneca | — | Lung Cancer | Active, not recruiting |
| 2027-05-31in 279 d | A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | AZNAstraZeneca | Phase 4 | COPD | Recruiting |
| 2027-05-31in 279 d | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | BIIBBiogen | Phase 3 | Immunoglobulin A Nephropathy (IgAN) | Recruiting |
| 2027-05-31in 279 d | Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis | BMYBristol-Myers Squibb | — | Idiopathic Pulmonary Fibrosis | Not yet recruiting |
| May 2027≤ 279 d | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | BOLTBolt Biotherapeutics, Inc. | Phase 1/2 | Gastroesophageal Cancer | Recruiting |
| 2027-05-31in 279 d | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | CGTXCognition Therapeutics | Phase 2 | Alzheimer's Disease | Active, not recruiting |
| May 2027≤ 279 d | A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | CRNXCrinetics Pharmaceuticals Inc. | Phase 3 | Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Recruiting |
| 2027-05-31in 279 d | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors | EXELExelixis | Phase 1 | Solid Tumors | Recruiting |
| 2027-05-31in 279 d | SpO2 Infant and Pediatric Study | GEHCGE Healthcare | Not applicable | SpO2 (Peripheral Oxygen Saturation) Measurement Validation, SpO2 | Not yet recruiting |
| May 2027≤ 279 d | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD | GENBGenerate Biomedicines | Phase 1 | Asthma | Active, not recruiting |
| May 2027≤ 279 d | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors | GILDGilead Sciences | Phase 1/2 | Solid Tumors | Active, not recruiting |
| May 2027≤ 279 d | Travoprost Intraocular Implant + iStent Infinite | GKOSGlaukos Corporation | Phase 4 | Glaucoma | Recruiting |
| 2027-05-31in 279 d | A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) | HLUN-B.COH. Lundbeck A/S | Phase 1 | Parkinson's Disease | Recruiting |
| May 2027≤ 279 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults | IBIOiBio, Inc. | Phase 1 | Overweight , Obesity | Recruiting |
| May 2027≤ 279 d | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | IBRXImmunityBio, Inc. | Phase 2 | Ovarian Cancer | Recruiting |
| May 2027≤ 279 d | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | IRONDisc Medicine, Inc | Phase 1/2 | Myelofibrosis | Recruiting |
| May 2027≤ 279 d | A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants | JBIOJade Biosciences, Inc. | Phase 1 | Healthy Volunteers (HV) | Recruiting |
| May 2027≤ 279 d | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | LLYEli Lilly and Company | Phase 2 | Neoplasms, Child, Adolescent | Recruiting |
| May 2027≤ 279 d | A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | LLYEli Lilly and Company | Phase 3 | Chronic Rhinosinusitis | Recruiting |
| May 2027≤ 279 d | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | LLYEli Lilly and Company | Phase 1 | Solid Tumors | Recruiting |
| May 2027≤ 279 d | LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | LLYEli Lilly and Company | Phase 2 | Ulcerative Colitis | Recruiting |
| May 2027≤ 279 d | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | LLYEli Lilly and Company | Phase 2 | Vitiligo, Non-Segmental Vitiligo (NSV) | Recruiting |
| May 2027≤ 279 d | A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | LLYEli Lilly and Company | Phase 3 | Type 2 Diabetes | Recruiting |
| May 2027≤ 279 d | Propel Drug-Eluting Sinus Implant Family IBUKI Cohort | MDTMedtronic | — | Chronic Rhinosinusitis | Recruiting |
| 2027-05-31in 279 d | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | ONCBeOne Medicines | Phase 1 | Mature B-Cell Malignancies | Active, not recruiting |
| May 2027≤ 279 d | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | RCUSArcus Biosciences, Inc. | Phase 1 | Pancreatic Cancer | Active, not recruiting |
| May 2027≤ 279 d | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | RCUSArcus Biosciences, Inc. | Phase 2 | Lung Cancer | Active, not recruiting |
| May 2027≤ 279 d | Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function | RCUSArcus Biosciences, Inc. | Phase 1 | Healthy Participants, Hepatic Impairment | Not yet recruiting |
| 2027-05-31in 279 d | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | RVMDRevolution Medicines, Inc. | Phase 1/2 | Lung Cancer | Recruiting |
| May 2027≤ 279 d | An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study) | SPTXSeaport Therapeutics | Phase 2 | Major Depressive Disorder | Enrolling by invitation |
| 2027-05-31in 279 d | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | SRPTSarepta Therapeutics, Inc. | Phase 3 | Duchenne Muscular Dystrophy | Active, not recruiting |
| May 2027≤ 279 d | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | TELOTelomir Pharmaceuticals, Inc. | Phase 1/2 | Breast Cancer | Not yet recruiting |
| May 2027≤ 279 d | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | VICO.STVicore Pharma AB | Phase 2 | Idiopathic Pulmonary Fibrosis | Active, not recruiting |
| May 2027≤ 279 d | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | VORVor Biopharma | Phase 3 | Myasthenia Gravis | Recruiting |
| 2027-05-31in 279 d | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Diabetic Peripheral Neuropathic Pain | Recruiting |
| May 2027≤ 279 d | A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection | VXRTVaxart | Phase 2 | COVID-19 | Active, not recruiting |
| May 2027≤ 279 d | VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | VYGRVoyager Therapeutics | Phase 1/2 | Alzheimer's Disease (AD) | Active, not recruiting |
| May 2027≤ 279 d | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | XENEXenon Pharmaceuticals Inc. | Phase 3 | Major Depressive Disorder | Recruiting |
| May 2027≤ 279 d | Study of XmAb412 in Healthy Participants | XNCRXencor, Inc. | Phase 1 | Not Applicable - Healthy Adult Participants | Recruiting |
| May 2027≤ 279 d | Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | ZURAZura Bio Inc | Phase 2 | Systemic Sclerosis | Active, not recruiting |
